Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.35 |
| ▸ | GSR | P00390 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865368 | 1.00 | GRIK1 (0.46) | GRIK1GRIK2CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL15265315 | 0.98 | GRIK1 (0.44) | GRIK1GRIK2CA1CA2CA7 | |
| Serine SCHEMBL457153 | 0.82 | GRIK1 (0.44) | GRIK1GRIK2CA1CA2CA7 | |
| Serine SCHEMBL457155 | 0.82 | GRIK1 (0.44) | GRIK1GRIK2CA1CA2CA7 | |
| SCHEMBL31037730 | 0.81 | NOS3 (0.44) | GRIK1GRIK2NOS3NOS1NOS2 | |
| SCHEMBL25661099 | 0.80 | NOS3 (0.47) | GRIK1GRIK2NOS3NOS1NOS2 | |
| SCHEMBL25660425 | 0.80 | NOS3 (0.49) | GRIK1GRIK2CA2NOS3NOS1 | |
| SCHEMBL25660421 | 0.80 | NOS3 (0.47) | GRIK1GRIK2NOS3NOS1NOS2 | |
| SCHEMBL25661103 | 0.80 | NOS3 (0.49) | GRIK1GRIK2CA2NOS3NOS1 | |
| SCHEMBL17434420 | 0.79 | NOS3 (0.53) | GRIK1GRIK2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027389-A1 | BIOLOGICALLY ACTIVE COMPOUNDS COMPRISING A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LIMITED (GB) | 2025-02-06 | — | — | WO | claimed |
| WO-2024069229-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2024-04-04 | — | — | WO | claimed |
| US-11944688-B2 | Biologically active compounds | SUTURA THERAPEUTICS LTD (GB) | 2024-04-02 | — | — | US | claimed |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2023-05-25 | — | — | US | claimed |
| US-20140255991-A1 | OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-09-11 | — | — | US | claimed |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2014-05-08 | — | — | US | claimed |
| EP-2640745-A2 | ANTIBODY DERIVATIVES | Allozyne, Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| WO-2012032181-A9 | ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2013-06-13 | — | — | WO | claimed |
| US-20120077228-A1 | OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-03-29 | — | — | US | claimed |
| WO-2012032181-A2 | NOVEL ANTIBODY DERIVATIVES | ALLOZYNE, INC (US) | 2012-03-15 | — | — | WO | claimed |
| US-7723070-B2 | Adding an desired amino acid analog to a medium containing a host cell with a vector coding for aminoacyl-tRNA synthetase and a vector coding for the polypeptide of interest; and growing the cell to produce the modified polypeptide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-05-25 | — | — | US | claimed |
| US-20080160609-A1 | Dihydrofolate reductase; site directed mutagenesis; point mutations; auxotroph host cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-07-03 | — | — | US | claimed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250352669-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS BY MODULATING THE EXPRESSION AND/OR ACTIVITY OF STUB1 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4580648-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCERS BY MODULATING THE EXPRESSION AND/OR ACTIVITY OF STUB1 | President and Fellows of Harvard College (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025027389-A1 | BIOLOGICALLY ACTIVE COMPOUNDS COMPRISING A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LIMITED (GB) | 2025-02-06 | — | — | WO | disclosed |
| US-7198915-B2 | Preparing modified/artificial polypeptides; mimetics | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040058415-A1 | Preparing modified/artificial polypeptides; mimetics | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-03-25 | — | — | US | disclosed |
| US-6586207-B2 | Host cell is a methionine auxotroph; methionine-tRNA synthetase overexpressed in presence of analogues and absence of methionine; protein is modified dihydrofolate reductase | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-07-01 | — | — | US | disclosed |
| US-20020042097-A1 | Host cell is a methionine auxotroph; methionine-tRNA synthetase overexpressed in presence of analogues and absence of methionine; protein is modified dihydrofolate reductase | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944688-B2 | Biologically active compounds | BPGM, PICALM, TMPO | GRIK1 4509/4885GRIK2 4276/4885CA1 863/4885 |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | GRIK1 4672/4885GRIK2 4291/4885CA1 1762/4885 |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | BPGM, PICALM, TMPO | GRIK1 4509/4885GRIK2 4276/4885CA1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.